Trial Profile

A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prexasertib (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

12 Mar 2020 Planned number of patients changed from 131 to 133.
02 May 2019 Status changed from active, no longer recruiting to completed.
08 Feb 2019 Planned number of patients changed from 116 to 131.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com